Nanoparticles Deliver iRNA’s
May 4, 2010 | Terry Sharrer
Cancer researchers and physicians are awaiting clinical outcome data that Mark Davis and colleagues will present at the June meeting of the American Society of Clinical Oncology about nanoparticle delivery of interfering RNA in a trial for melanoma. Recently, Davis, professor of chemical engineering at CalTech, reported in Nature that the dose of this therapy corresponded with the amount that reached the tumor cells in the skin. The silencing RNA targeted the gene for ribonucleotide reductase M2-a regulator of DNA synthesis and repair. MORE